Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine
Hypertension

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion criteria:
- Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be >=90 and <=114 mmHg and mean seated systolic blood pressure (SBP) must be =<200 mmHg
- Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion
- Age 20 years or older
Exclusion criteria:
- Patients with known or suspected secondary hypertension
- Patients with clinically relevant cardiac arrhythmia
- Congestive heart failure with New York Heart Association (NYHA) functional class III-IV
- Patients with recent cardiovascular events
- Patients with recent stroke events
- Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy
- Patients with hepatic and/or renal dysfunction
- Pre-menopausal women who are nursing or pregnant
Sites / Locations
- 1348.2.020 Boehringer Ingelheim Investigational Site
- 1348.2.008 Boehringer Ingelheim Investigational Site
- 1348.2.018 Boehringer Ingelheim Investigational Site
- 1348.2.006 Boehringer Ingelheim Investigational Site
- 1348.2.013 Boehringer Ingelheim Investigational Site
- 1348.2.021 Boehringer Ingelheim Investigational Site
- 1348.2.012 Boehringer Ingelheim Investigational Site
- 1348.2.011 Boehringer Ingelheim Investigational Site
- 1348.2.001 Boehringer Ingelheim Investigational Site
- 1348.2.019 Boehringer Ingelheim Investigational Site
- 1348.2.014 Boehringer Ingelheim Investigational Site
- 1348.2.002 Boehringer Ingelheim Investigational Site
- 1348.2.007 Boehringer Ingelheim Investigational Site
- 1348.2.009 Boehringer Ingelheim Investigational Site
- 1348.2.005 Boehringer Ingelheim Investigational Site
- 1348.2.016 Boehringer Ingelheim Investigational Site
- 1348.2.010 Boehringer Ingelheim Investigational Site
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
telmisartan + HCTZ + amlodipine
telmisartan + HCTZ + placebo
telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)